Hot Features
Premium
Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Aptinyx Inc | APTX | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.061 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.061 | 0.061 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 0.061 - 0.1475 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 0.061 | USD |
Aptinyx Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| US$ 4.13M | - | - | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Aptinyx News
| Date | Time | Source | News Article |
|---|---|---|---|
| 12/21/2023 | 09:52 | Edgar (US Regulatory) | Form 8-K - Current report |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical APTX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Year | 0.1298 | 0.1475 | 0.061 | 0.0922868 | 3,339,166 | -0.0688 | -53.00% |
| 3 Years | 2.68 | 4.73 | 0.061 | 0.8883754 | 886,031 | -2.62 | -97.72% |
| 5 Years | 3.61 | 6.47 | 0.061 | 1.82 | 669,421 | -3.55 | -98.31% |
Aptinyx Description
| Aptinyx Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel, proprietary, synthetic small molecules for the treatment of brain and nervous system disorders. Its pipeline products are NYX-2925, NYX-458, and NYX-783. NYX-2925 is a novel, oral, small-molecule NMDA receptor modulator in clinical development as a therapy for chronic pain. NYX-2925 works by enhancing synaptic plasticity, a mechanism uniquely suited to addressing chronic pain, and NYX-783 is an NMDA receptor modulating small molecule in clinical development as a therapy for post-traumatic stress disorder. |
